This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Final order imposing conditions on AbbVie’s acquisition of Allergan approved by US FTC

( September 4, 2020, 17:40 GMT | Official Statement) -- MLex Summary: The US Federal Trade Commission approved a final order settling charges that AbbVie’s $63 billion acquisition of Allergan would violate federal antitrust law. Under the order, AbbVie and Allergan will divest, to Nestlé, Allergan’s Zenpep and Viokase, used to treat pancreatic insufficiency. AbbVie and Allergan also must divest to AstraZeneca Allergan’s rights and assets related to brazikumab, a treatment for moderate-to-severe Crohn’s disease and ulcerative colitis.Statement follows in full. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login